, Celltrion of S Korea receives US emergency approval for rapid test Sampinute
South Korean biopharma company has got emergency use approval (EUA) from the US authorities for its rapid test Sampinute that has an accuracy rate of 94% and a turnaround time of 10 minutes. It has another rapid test in the pipeline awaiting EUA, which can be used in a clinical setting.
